Revvity ($RVTY) Stock Forecast: Up 5.1% Today

What is Revvity?

Revvity (RVTY) is expected to see a decline in Q1 earnings, as projected by analysts.

Why is Revvity going up?

RVTY stock is up 5.1% on Apr 22, 2025 16:47

• Regarding the current market movement of RVTY:
• Investors may be looking at potential growth opportunities and recent strategic partnerships rather than the projected decline in Q1 earnings.
• Speculation about a possible recovery in the following quarters could be sparking increased buying activity.
• Positive market sentiment and broader industry trends might be influencing the stock's upward movement despite the anticipated drop in earnings.
• Insider information or market rumors could potentially be contributing to the rise in stock price, disregarding the predicted earnings decrease.

RVTY Price Chart

RVTY Technical Analysis

RVTY News

Earnings Preview: Revvity ( RVTY ) Q1 Earnings Expected to Decline

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

https://www.zacks.com/stock/news/2451854/earnings-preview-revvity-rvty-q1-earnings-expected-to-decline

Trending Today

Monero ($XMR) Crypto Forecast: Up 5.1% Today

Movement ($MOVE) Crypto Forecast: Up 5.2% Today

Worldcoin ($WLD) Crypto Forecast: Up 5.7% Today

Bonk ($BONK) Crypto Forecast: Down 5.9% Today

S&P 500 Index ($SPX) Index Forecast: Up 0.6% Today

NASDAQ-100 ($NDX) Index Forecast: Up 1.0% Today

Chegg Inc. ($CHGG) Stock Forecast: Up 6.6% Today

PPG Industries Inc. ($PPG) Stock Forecast: Up 5.0% Today

Spotify Technology S.A. ($SPOT) Stock Forecast: Up 5.8% Today

Algorand ($ALGO) Crypto Forecast: Down 5.9% Today

Revvity Price History

22.03.2025 - RVTY Stock was up 5.1%

• Regarding the current market movement of RVTY:
• Investors may be looking at potential growth opportunities and recent strategic partnerships rather than the projected decline in Q1 earnings.
• Speculation about a possible recovery in the following quarters could be sparking increased buying activity.
• Positive market sentiment and broader industry trends might be influencing the stock's upward movement despite the anticipated drop in earnings.
• Insider information or market rumors could potentially be contributing to the rise in stock price, disregarding the predicted earnings decrease.

14.10.2023 - RVTY Stock was up 5.0%

• The investigation by Pomerantz LLP might have caused some uncertainty among investors, but it did not have a significant impact on the stock's bullish movement.
• Other positive factors, such as strong financial performance or favorable market conditions, likely contributed to the bullish movement of RVTY.
• Investors may have been optimistic about the future prospects of Revvity, Inc., leading to increased buying interest and driving the stock price higher.
• It is important to monitor any developments related to the investigation by Pomerantz LLP to assess any potential impact on the stock in the future.

04.10.2024 - RVTY Stock was up 3.0%

• RVTY surpassed Q3 earnings and revenue estimates, showing strong financial performance.
• The positive earnings surprise hints at solid performance in the Diagnostics segment.
• Despite facing challenges in the Life Sciences segment, the overall performance exceeded expectations, prompting the stock's bullish movement.
• Investor confidence in the company's future likely increased following the Q3 results.

13.01.2024 - RVTY Stock was down 5.0%

• The recent introduction of Revvity's clinical data science platform may not have a direct connection to RVTY's decline in the market.
• Various other factors, including weak financial performance or unfavorable market sentiment, could have played a role in the stock's downward trend.
• It is crucial to take into account any other developments or occurrences that might have impacted RVTY's bearish movement.

31.09.2023 - RVTY Stock was down 8.4%

• Revvity's Q3 report and lowered forecast contributed to the bearish movement in its stock.
• The company's earnings and sales missed estimates, reflecting the impact of increased market uncertainty.
• The demand from its pharma and biotech customers fell, further adding to the negative sentiment.
• The disappointing performance of Revvity also had a spillover effect on other life science tool providers, dragging down their stocks as well.

25.09.2023 - RVTY Stock was down 5.1%

• The decline in earnings is likely a significant factor contributing to the bearish movement of Revvity's stock today.
• The lack of a positive earnings beat expectation may have disappointed investors and led to selling pressure on the stock.
• The new partnership announcement, although positive for the long-term prospects of the company, may not have been enough to offset the negative sentiment surrounding the earnings decline.

03.10.2023 - RVTY Stock was up 5.3%

• Revvity's disappointing Q3 report and lowered forecast initially caused a plunge in the stock, but it managed to recover and have a bullish movement.
• The company's earnings and sales missed estimates, reflecting the impact of increased market uncertainty.
• Despite the negative news, some articles suggest that Revvity is an undervalued gem in the medical diagnostics and research industry.
• Other life science tool providers may have been affected by Revvity's performance, leading to a broader bearish sentiment in the industry.

30.09.2023 - RVTY Stock was down 4.6%

• Revvity reported Q3 financial results that missed both top and bottom line estimates, with a lower-than-expected Non-GAAP EPS of $1.18 and a revenue of $670.74M (-5.8% Y/Y).
• The company's GAAP earnings per share for the quarter were $0.08, compared to $0.67 in the same period last year, and GAAP revenue decreased from $712 million to $671 million year-over-year.
• Analysts had estimated an EPS of $1.19 and a revenue of $694.52M for the quarter, which were not met by Revvity.
• Additionally, Revvity declared a quarterly dividend of $0.07 per share, which may have influenced investor sentiment.
• Overall, Revvity's weaker-than-expected financial results and missed estimates likely contributed to the bearish movement of the stock today.

03.03.2025 - RVTY Stock was down 5.1%

• The recent approval of Revvity's Auto-Pure 2400 platform by the FDA for high-throughput latent TB testing is a positive development reflecting improved accuracy and efficiency in disease diagnosis and treatment.
• Nevertheless, the market displayed a bearish reaction, potentially due to investors opting to secure profits after anticipating the FDA's approval.
• Concerns regarding competition in healthcare technology or broader market circumstances impacting RVTY's stock price could also have influenced the bearish sentiment among investors.
• Although the FDA approval marked a significant achievement for Revvity, short-term market forces and investor outlook likely contributed to the decline in RVTY stock value today.

11.06.2024 - RVTY Stock was up 6.2%

• Investors are displaying confidence in Revvity, Inc. prior to its earnings call, indicating high hopes for favorable financial outcomes.
• The upcoming executive conference call demonstrates a commitment to transparency and proactive communication with shareholders, likely enhancing investor trust.
• The upward movement in the stock price may be attributed to expectations of strong performance in the second quarter, potentially driven by effective business strategies or initiatives for revenue growth.

27.01.2025 - RVTY Stock was down 5.3%

• Options market activities indicate potential insider information or speculation impacting Revvity's performance, leading to heightened selling pressure.
• Concerns or uncertainties regarding Revvity's future plans or financial outcomes may be influencing investors to adopt a more careful stance.
• The stock's downturn could also stem from traders cashing in profits after benefiting from its earlier positive performance, resulting in a temporary decrease in value.